Cetirizine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Cetirizine: From Established Antihistamine Use to Allergic Urticaria
One-Sentence Summary
Cetirizine is a second-generation H1-antihistamine widely used for allergic conditions; a formal record of its originally approved indication is not present in this evidence pack. The TxGNN model’s top prediction identifies Allergic Urticaria as the strongest candidate indication, with a prediction score of 99.99%, supported by 3 clinical trials and 18 publications, including one completed Phase 3 trial and a 2021 systematic review.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in the available regulatory dataset (taiwan_regulatory.licenses and drug.original_indications are empty) |
| Predicted New Indication | Allergic Urticaria |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L1 |
| Australia Market Status | Not currently marketed (per dataset) |
| Number of ARTG Entries | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, a formal mechanism-of-action record (DrugBank original_moa) is not available in this evidence pack. Based on the pharmacological detail captured in the repurposing evidence itself, cetirizine is a second-generation H1-histamine receptor inverse agonist that directly blocks histamine-driven vasodilation, increased vascular permeability, and pruritus — the core pathophysiological pathway underlying urticaria.
Because drug.original_indications was not populated in this extract, the originally approved indication wording cannot be quoted directly. However, the evidence supplied for this candidate is unusual among repurposing predictions: the reviewer-provided rationale notes that allergic urticaria is essentially not a novel indication for cetirizine but rather a reconfirmation of an already well-established, guideline-endorsed use of second-generation antihistamines (allergic and chronic urticaria).
Mechanistically, this is consistent — H1-receptor blockade is the accepted first-line pharmacological approach to histamine-mediated urticaria, and the same mechanism underlies the lower-ranked, related predictions in this pack (e.g., cold urticaria, angioedema), which show progressively weaker direct evidence as the disease mechanism moves further from classical histamine-driven pathology.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT02023164 | Phase 3 | Completed | 36 | Multicentre pilot RCT of IV cetirizine 10 mg vs IV diphenhydramine 50 mg for acute urticaria in ED/urgent care settings; feasibility study directly testing cetirizine in this indication. |
| NCT03296358 | N/A | Completed | 75 | Randomised, double-blind trial assessing whether adding a short corticosteroid burst to conventional H1-antihistamine treatment improves outcomes in urticaria; antihistamine background therapy, corticosteroid is the primary studied intervention. |
| NCT01008592 | N/A | Terminated | 11 | Evaluated levocetirizine (the active enantiomer of cetirizine) effects on skin inflammatory mediators (histamine, proteases, PGE2, LTB4) in dermatographism and chronic idiopathic urticaria; trial terminated early, limiting evidentiary weight. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33030434 | 2021 | Systematic Review | J Investig Allergol Clin Immunol | Systematic review of efficacy/safety of up-dosing second-generation antihistamines (up to 4x licensed dose) in chronic spontaneous urticaria when standard dosing fails. |
| 7645679 | 1995 | Clinical trial review | Allergy | Review of clinical studies specifically evaluating cetirizine in allergic rhinitis and chronic urticaria. |
| 7510611 | 1993 | Review | Drugs | Pharmacological reappraisal of cetirizine; reports it as effective and well-tolerated for seasonal/perennial allergic rhinitis and chronic idiopathic urticaria in adults. |
| 1981354 | 1990 | Review | Drugs | Reviews cetirizine’s H1-receptor affinity, lack of CNS depressant effect at standard 10 mg dose, and inhibition of histamine release/eosinophil chemotaxis relevant to allergic urticaria. |
| 8477125 | 1993 | Review | Ann Pharmacother | Introduces cetirizine as a nonsedating antihistamine, covering mechanism of action, clinical/comparative trial data, and adverse effects. |
| 9951950 | 1999 | Review | Drugs | Comparative review of second-generation antihistamines (including cetirizine) evaluating features relevant to clinical choice. |
| 18201439 | 2007 | Review | Allergy Asthma Proc | Reviews levocetirizine (cetirizine’s active enantiomer) pharmacology, safety, and effectiveness in allergic rhinitis and chronic idiopathic urticaria. |
| 16278258 | 2005 | Review | Ann Pharmacother | Reviews efficacy and safety of oral antihistamines, including cetirizine, for allergic rhinitis and chronic idiopathic urticaria, with a pharmacy management focus. |
| 7530629 | 1994 | Review | Drugs | Reviews recognition, causes and treatment of urticaria, noting nonsedating antihistamines as mainstay therapy. |
| 41602253 | 2025 | Case Report | Cureus | Case report of rebound pruritus/urticaria following discontinuation of chronic cetirizine use in an Asian patient — relevant safety observation for long-term use. |
Australia Market Information
No ARTG entries are recorded for this product in the currently available dataset (taiwan_regulatory.total_licenses = 0). Market status is reported as not currently marketed in this data source. This should be independently verified against the current TGA/ARTG register, as it directly affects Blocking Data Gap DG001 (TFDA/TGA product information).
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information. No key warnings, contraindications, or drug–drug interaction data are currently available in this evidence pack (DDI query status: not found).
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The top-ranked prediction (allergic urticaria) is supported by L1-level evidence, including one completed Phase 3 trial directly testing cetirizine and a 2021 systematic review on antihistamine dosing in chronic urticaria. However, the underlying regulatory (TGA/ARTG) and mechanism-of-action data needed for a full safety evaluation are currently missing, so the recommendation stops short of an unconditional “Go.”
To proceed, the following is needed:
- TGA-approved Product Information — warnings and contraindications (Blocking gap, DG001)
- Confirmed mechanism-of-action documentation from DrugBank or equivalent source (High priority gap, DG002)
- Verified current ARTG registration status and licensed indication wording for cetirizine in Australia
- Drug–drug interaction data (current query returned no results)
- Clinical evaluation of lower-ranked, mechanistically weaker candidates (cold urticaria, angioedema) only after the above gaps are closed
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.